Displaying items 121-124 of 124 in total
CERo Therapeutics reports early safety success and dose escalation in its Phase 1 AML trial for CER-1236, a novel cell therapy for high-risk patients.
Beyond vaccines, Strand Therapeutics' programmable mRNA shows stunning success in late-stage cancer, heralding a new age of logic-driven genetic medicine.
Early Phase 1 data for VTP-1000 shows promise, but can this novel immunotherapy challenge a crowded market and change life for 80 million patients?
SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.
Get your daily brief delivered to your inbox every morning at 7am
